COPYRIGHT © BY THE JOURNAL OF BONE AND JOINT SURGERY, INCORPORATED CHISARI ET AL. ASPIRIN IS AN EFFECTIVE PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN AMBULATORY PATIENTS WITH FEMORAL NECK FRACTURE UNDERGOING HIP ARTHROPLASTY http://dx.doi.org/10.2106/JBJS.21.00168 Page 1

The following content was supplied by the authors as supporting material and has not been copy-edited or verified by JBJS.

Appendix

This write up is looking at the updated breakdowns for CCI, ASA, and Elixhauser.

	No Aspirin	Aspirin	P Value
	N=343	N=269	
CCI:			<0.001
0	249 (72.6%)	224 (86.2%)	
1	18 (5.25%)	13 (5.00%)	
2	25 (7.29%)	5 (1.92%)	
3	12 (3.50%)	7 (2.69%)	
4	15 (4.37%)	3 (1.15%)	
5	9 (2.62%)	6 (2.31%)	
6	6 (1.75%)	0 (0.00%)	
7	1 (0.29%)	0 (0.00%)	
8	1 (0.29%)	0 (0.00%)	
9	2 (0.58%)	1 (0.38%)	
10	2 (0.58%)	1 (0.38%)	
11	2 (0.58%)	0 (0.00%)	
13	1 (0.29%)	0 (0.00%)	
ASA:			<0.001
0	2 (0.94%)	0 (0.00%)	
1	0 (0.00%)	10 (4.90%)	
2	40 (18.8%)	69 (33.8%)	
3	157 (73.7%)	125 (61.3%)	
4	14 (6.57%)	0 (0.00%)	
Elixhauser:			<0.001
0	235 (68.5%)	225 (83.6%)	
1	7 (2.04%)	3 (1.12%)	
2	9 (2.62%)	2 (0.74%)	
3	7 (2.04%)	5 (1.86%)	

Table 1. The THA full cohort

ASPIRIN IS AN EFFECTIVE PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN AMBULATORY PATIENTS WITH FEMORAL NECK FRACTURE UNDERGOING HIP ARTHROPLASTY

http://dx.doi.org/10.2106/JBJS.21.00168

Page 2

		· · · · · · · · · · · · · · · · · · ·
4	5 (1.46%)	1 (0.37%)
5	13 (3.79%)	4 (1.49%)
6	3 (0.87%)	2 (0.74%)
7	1 (0.29%)	1 (0.37%)
8	5 (1.46%)	3 (1.12%)
9	4 (1.17%)	1 (0.37%)
10	5 (1.46%)	3 (1.12%)
11	4 (1.17%)	1 (0.37%)
12	2 (0.58%)	1 (0.37%)
13	2 (0.58%)	2 (0.74%)
14	6 (1.75%)	1 (0.37%)
15	3 (0.87%)	1 (0.37%)
16	1 (0.29%)	0 (0.00%)
17	4 (1.17%)	0 (0.00%)
18	3 (0.87%)	0 (0.00%)
19	1 (0.29%)	0 (0.00%)
20	2 (0.58%)	1 (0.37%)
22	0 (0.00%)	1 (0.37%)
23	0 (0.00%)	2 (0.74%)
24	2 (0.58%)	0 (0.00%)
25	1 (0.29%)	1 (0.37%)
26	2 (0.58%)	0 (0.00%)
28	1 (0.29%)	0 (0.00%)
29	1 (0.29%)	0 (0.00%)
31	1 (0.29%)	0 (0.00%)
32	1 (0.29%)	0 (0.00%)
37	0 (0.00%)	1 (0.37%)

Table 2. THA and High risk only

	No Aspirin	Aspirin	P Value
	N=111	N=16	
CCI:			1.000
0	104 (93.7%)	15 (100%)	
1	1 (0.90%)	0 (0.00%)	
2	2 (1.80%)	0 (0.00%)	

ASPIRIN IS AN EFFECTIVE PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN AMBULATORY PATIENTS WITH FEMORAL NECK FRACTURE UNDERGOING HIP ARTHROPLASTY

http://dx.doi.org/10.2106/JBJS.21.00168

Page 3

1 (0.90%)	0 (0.00%)	
1 (0.90%)	0 (0.00%)	
1 (0.90%)	0 (0.00%)	
1 (0.90%)	0 (0.00%)	
		1.000
18 (17.3%)	3 (18.8%)	
80 (76.9%)	13 (81.2%)	
6 (5.77%)	0 (0.00%)	
		1.000
104 (93.7%)	16 (100%)	
1 (0.90%)	0 (0.00%)	
1 (0.90%)	0 (0.00%)	
1 (0.90%)	0 (0.00%)	
1 (0.90%)	0 (0.00%)	
1 (0.90%)	0 (0.00%)	
1 (0.90%)	0 (0.00%)	
1 (0.90%)	0 (0.00%)	
	1 (0.90%) 1 (0.90%) 1 (0.90%) 18 (17.3%) 80 (76.9%) 6 (5.77%) 104 (93.7%) 1 (0.90%) 1 (0.90%) 1 (0.90%) 1 (0.90%) 1 (0.90%) 1 (0.90%) 1 (0.90%)	1 (0.90%) 0 (0.00%) 1 (0.90%) 0 (0.00%) 1 (0.90%) 0 (0.00%) 1 (0.90%) 0 (0.00%) 1 (0.90%) 0 (0.00%) 18 (17.3%) 3 (18.8%) 80 (76.9%) 13 (81.2%) 6 (5.77%) 0 (0.00%) 104 (93.7%) 16 (100%) 1 (0.90%) 0 (0.00%) 1 (0.90%) 0 (0.00%) 1 (0.90%) 0 (0.00%) 1 (0.90%) 0 (0.00%) 1 (0.90%) 0 (0.00%) 1 (0.90%) 0 (0.00%) 1 (0.90%) 0 (0.00%) 1 (0.90%) 0 (0.00%)

Table 3. THA and Standard risk only

	No Aspirin	Aspirin	P Value
	N=232	N=253	
CCI:			<0.001
0	145 (62.5%)	209 (85.3%)	
1	17 (7.33%)	13 (5.31%)	
2	23 (9.91%)	5 (2.04%)	
3	11 (4.74%)	7 (2.86%)	
4	15 (6.47%)	3 (1.22%)	
5	9 (3.88%)	6 (2.45%)	
6	5 (2.16%)	0 (0.00%)	
7	1 (0.43%)	0 (0.00%)	
9	2 (0.86%)	1 (0.41%)	
10	2 (0.86%)	1 (0.41%)	
11	1 (0.43%)	0 (0.00%)	
13	1 (0.43%)	0 (0.00%)	
ASA:			<0.001

ASPIRIN IS AN EFFECTIVE PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN AMBULATORY PATIENTS WITH FEMORAL NECK FRACTURE UNDERGOING HIP ARTHROPLASTY

http://dx.doi.org/10.2106/JBJS.21.00168

0	2 (1.83%)	0 (0.00%)	
1	0 (0.00%)	10 (5.32%)	
2	22 (20.2%)	66 (35.1%)	
3	77 (70.6%)	112 (59.6%)	
4	8 (7.34%)	0 (0.00%)	
Elixhauser:			<0.001
0	131 (56.5%)	209 (82.6%)	
1	7 (3.02%)	3 (1.19%)	
2	9 (3.88%)	2 (0.79%)	
3	7 (3.02%)	5 (1.98%)	
4	5 (2.16%)	1 (0.40%)	
5	13 (5.60%)	4 (1.58%)	
6	3 (1.29%)	2 (0.79%)	
7	1 (0.43%)	1 (0.40%)	
8	5 (2.16%)	3 (1.19%)	
9	4 (1.72%)	1 (0.40%)	
10	5 (2.16%)	3 (1.19%)	
11	4 (1.72%)	1 (0.40%)	
12	2 (0.86%)	1 (0.40%)	
13	2 (0.86%)	2 (0.79%)	
14	6 (2.59%)	1 (0.40%)	
15	3 (1.29%)	1 (0.40%)	
16	1 (0.43%)	0 (0.00%)	
17	4 (1.72%)	0 (0.00%)	
18	2 (0.86%)	0 (0.00%)	
20	1 (0.43%)	1 (0.40%)	
22	0 (0.00%)	1 (0.40%)	
23	0 (0.00%)	2 (0.79%)	
24	1 (0.43%)	0 (0.00%)	
25	0 (0.00%)	1 (0.40%)	
26	2 (0.86%)	0 (0.00%)	
28	1 (0.43%)	0 (0.00%)	
31	1 (0.43%)	0 (0.00%)	
37	0 (0.00%)	1 (0.40%)	

COPYRIGHT © BY THE JOURNAL OF BONE AND JOINT SURGERY, INCORPORATED CHISARI ET AL. ASPIRIN IS AN EFFECTIVE PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN AMBULATORY PATIENTS WITH FEMORAL NECK FRACTURE UNDERGOING HIP ARTHROPLASTY http://dx.doi.org/10.2106/JBJS.21.00168

Page 5

Table 4. The HA fu	No Aspirin	Aspirin	P Value
	N=329	N=182	
CCI:			<0.001
0	197 (59.9%)	116 (67.1%)	
1	40 (12.2%)	17 (9.83%)	
2	17 (5.17%)	10 (5.78%)	
3	16 (4.86%)	8 (4.62%)	
4	12 (3.65%)	8 (4.62%)	
5	16 (4.86%)	4 (2.31%)	
6	16 (4.86%)	3 (1.73%)	
7	4 (1.22%)	1 (0.58%)	
8	6 (1.82%)	4 (2.31%)	
9	2 (0.61%)	1 (0.58%)	
10	2 (0.61%)	1 (0.58%)	
11	1 (0.30%)	0 (0.00%)	
ASA:			<0.001
1	0 (0.00%)	6 (5.71%)	
2	23 (15.6%)	32 (30.5%)	
3	115 (78.2%)	65 (61.9%)	
4	9 (6.12%)	2 (1.90%)	
Elixhauser:			<0.001
0	177 (53.8%)	120 (65.9%)	
1	1 (0.30%)	0 (0.00%)	
2	13 (3.95%)	4 (2.20%)	
3	5 (1.52%)	4 (2.20%)	
4	6 (1.82%)	2 (1.10%)	
5	23 (6.99%)	11 (6.04%)	
6	6 (1.82%)	4 (2.20%)	
7	9 (2.74%)	2 (1.10%)	
8	3 (0.91%)	0 (0.00%)	
9	10 (3.04%)	2 (1.10%)	
10	3 (0.91%)	0 (0.00%)	
11	7 (2.13%)	4 (2.20%)	

Table 4. The HA full cohort.

ASPIRIN IS AN EFFECTIVE PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN AMBULATORY PATIENTS WITH FEMORAL NECK FRACTURE UNDERGOING HIP ARTHROPLASTY

http://dx.doi.org/10.2106/JBJS.21.00168

12	10 (3.04%)	4 (2.20%)	
13	2 (0.61%)	1 (0.55%)	
14	6 (1.82%)	0 (0.00%)	
15	4 (1.22%)	4 (2.20%)	
16	3 (0.91%)	2 (1.10%)	
17	4 (1.22%)	1 (0.55%)	
18	2 (0.61%)	0 (0.00%)	
19	2 (0.61%)	4 (2.20%)	
20	1 (0.30%)	1 (0.55%)	
21	3 (0.91%)	1 (0.55%)	
22	1 (0.30%)	2 (1.10%)	
23	2 (0.61%)	1 (0.55%)	
24	2 (0.61%)	0 (0.00%)	
25	2 (0.61%)	1 (0.55%)	
26	3 (0.91%)	0 (0.00%)	
27	1 (0.30%)	0 (0.00%)	
28	1 (0.30%)	0 (0.00%)	
29	1 (0.30%)	0 (0.00%)	
30	0 (0.00%)	3 (1.65%)	
31	1 (0.30%)	0 (0.00%)	
33	3 (0.91%)	0 (0.00%)	
37	3 (0.91%)	0 (0.00%)	
40	1 (0.30%)	0 (0.00%)	
45	1 (0.30%)	0 (0.00%)	

Table 5. HA and High risk only

	No Aspirin	Aspirin	P Value
	N=78	N=22	
CCI:			0.498
0	69 (88.5%)	17 (85.0%)	
1	2 (2.56%)	0 (0.00%)	
4	0 (0.00%)	1 (5.00%)	
5	3 (3.85%)	1 (5.00%)	
7	1 (1.28%)	0 (0.00%)	
8	3 (3.85%)	1 (5.00%)	

ASPIRIN IS AN EFFECTIVE PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN AMBULATORY PATIENTS WITH FEMORAL NECK FRACTURE UNDERGOING HIP ARTHROPLASTY

http://dx.doi.org/10.2106/JBJS.21.00168

Page 7

ASA:			0.363
2	9 (12.9%)	4 (21.1%)	
3	56 (80.0%)	15 (78.9%)	
4	5 (7.14%)	0 (0.00%)	
Elixhauser:			0.406
0	69 (88.5%)	19 (86.4%)	
5	1 (1.28%)	0 (0.00%)	
20	1 (1.28%)	0 (0.00%)	
23	1 (1.28%)	1 (4.55%)	
26	1 (1.28%)	0 (0.00%)	
27	1 (1.28%)	0 (0.00%)	
30	0 (0.00%)	2 (9.09%)	
33	1 (1.28%)	0 (0.00%)	
37	2 (2.56%)	0 (0.00%)	
45	1 (1.28%)	0 (0.00%)	

Table 6. HA and Standard risk only

	No Aspirin	Aspirin	P Value
	N=251	N=160	
CCI:			<0.001
0	128 (51.0%)	99 (64.7%)	
1	38 (15.1%)	17 (11.1%)	
2	17 (6.77%)	10 (6.54%)	
3	16 (6.37%)	8 (5.23%)	
4	12 (4.78%)	7 (4.58%)	
5	13 (5.18%)	3 (1.96%)	
6	16 (6.37%)	3 (1.96%)	
7	3 (1.20%)	1 (0.65%)	
8	3 (1.20%)	3 (1.96%)	
9	2 (0.80%)	1 (0.65%)	
10	2 (0.80%)	1 (0.65%)	
11	1 (0.40%)	0 (0.00%)	
ASA:			0.005
1	0 (0.00%)	6 (6.98%)	
2	14 (18.2%)	28 (32.6%)	

ASPIRIN IS AN EFFECTIVE PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN AMBULATORY PATIENTS WITH FEMORAL NECK FRACTURE UNDERGOING HIP ARTHROPLASTY

http://dx.doi.org/10.2106/JBJS.21.00168

3	59 (76.6%)	50 (58.1%)	
4	4 (5.19%)	2 (2.33%)	
Elixhauser:			<0.001
0	108 (43.0%)	101 (63.1%)	
1	1 (0.40%)	0 (0.00%)	
2	13 (5.18%)	4 (2.50%)	
3	5 (1.99%)	4 (2.50%)	
4	6 (2.39%)	2 (1.25%)	
5	22 (8.76%)	11 (6.88%)	
6	6 (2.39%)	4 (2.50%)	
7	9 (3.59%)	2 (1.25%)	
8	3 (1.20%)	0 (0.00%)	
9	10 (3.98%)	2 (1.25%)	
10	3 (1.20%)	0 (0.00%)	
11	7 (2.79%)	4 (2.50%)	
12	10 (3.98%)	4 (2.50%)	
13	2 (0.80%)	1 (0.62%)	
14	6 (2.39%)	0 (0.00%)	
15	4 (1.59%)	4 (2.50%)	
16	3 (1.20%)	2 (1.25%)	
17	4 (1.59%)	1 (0.62%)	
18	2 (0.80%)	0 (0.00%)	
19	2 (0.80%)	4 (2.50%)	
20	0 (0.00%)	1 (0.62%)	
21	3 (1.20%)	1 (0.62%)	
22	1 (0.40%)	2 (1.25%)	
23	1 (0.40%)	0 (0.00%)	
24	2 (0.80%)	0 (0.00%)	
25	2 (0.80%)	1 (0.62%)	
26	2 (0.80%)	0 (0.00%)	
28	1 (0.40%)	0 (0.00%)	
29	1 (0.40%)	0 (0.00%)	
30	0 (0.00%)	1 (0.62%)	
31	1 (0.40%)	0 (0.00%)	
33	2 (0.80%)	0 (0.00%)	

COPYRIGHT © BY THE JOURNAL OF BONE AND JOINT SURGERY, INCORPORATED CHISARI ET AL. ASPIRIN IS AN EFFECTIVE PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN AMBULATORY PATIENTS WITH FEMORAL NECK

FRACTURE UNDERGOING HIP ARTHROPLASTY

http://dx.doi.org/10.2106/JBJS.21.00168

37	1 (0.40%)	0 (0.00%)	
40	1 (0.40%)	0 (0.00%)	